1
|
Han JE, Park MK, Jin JH, Lee JA, Park G, Park JS, Bae HI, Yun SJ, Seo AN, Han MH, Lee H, Jeon JP, Yu JI, Kim SS, Cheong JY. Consensus Definition of Blood Samples from the Subcategorized Normal Controls in the Korea Biobank Network. J Clin Med 2023; 12:3080. [PMID: 37176521 PMCID: PMC10179422 DOI: 10.3390/jcm12093080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Revised: 02/27/2023] [Accepted: 04/20/2023] [Indexed: 05/15/2023] Open
Abstract
A control group is defined as a group of people used for comparison. Depending on the type of study, it can be a group of healthy people or a group not exposed to risk factors. It is important to allow researchers to select the appropriate control participants. The Korea Biobank Project-sponsored biobanks are affiliated with the Korea Biobank Network (KBN), for which the National Biobank of Korea plays a central coordinating role among KBN biobanks. KBN organized several working groups to address new challenges and needs in biobanking. The "Normal Healthy Control Working Group" developed standardized criteria for three defined control groups, namely, normal, normal-plus, and disease-specific controls. Based on the consensus on the definition of a normal control, we applied the criteria for normal control participants to retrospective data. The main reason for exclusion from the "Normal-plus" group was blood test results beyond 5% of the reference range, including hypercholesterolemia. Subclassification of samples of normal controls by detailed criteria will help researchers select optimal normal controls for their studies.
Collapse
Affiliation(s)
- Ji Eun Han
- Department of Gastroenterology, Ajou University Hospital, Suwon 16499, Republic of Korea
| | - Min Kyu Park
- Department of Clinical Pharmacology and Therapeutics, College of Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea
| | - Ju Hyun Jin
- Human Genome Research & Bio-Resource Center, Ajou University Hospital, Suwon 16499, Republic of Korea
| | - Jung Ah Lee
- Human Genome Research & Bio-Resource Center, Ajou University Hospital, Suwon 16499, Republic of Korea
| | - Gyeongsin Park
- The Biobank of Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 03382, Republic of Korea
- Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
| | - Jong Sook Park
- Department of Allergy & Pulmonology, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Republic of Korea
| | - Han-Ik Bae
- Department of Pathology, Kyungpook National University Hospital, Daegu 41404, Republic of Korea
| | - Seok Joong Yun
- Department of Urology, College of Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea
- Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea
| | - An Na Seo
- Department of Pathology, Kyungpook National University Hospital, Daegu 41404, Republic of Korea
| | - Man-Hoon Han
- Department of Pathology, Kyungpook National University Hospital, Daegu 41404, Republic of Korea
| | - Hyoungnam Lee
- The Biobank of Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 03382, Republic of Korea
| | - Jae-Pil Jeon
- Division of Biobank, Department of Precision Medicine, Korea National Institute of Health, Cheongju 28159, Republic of Korea
| | - Ji-In Yu
- Division of Biobank, Department of Precision Medicine, Korea National Institute of Health, Cheongju 28159, Republic of Korea
| | - Soon Sun Kim
- Department of Gastroenterology, Ajou University Hospital, Suwon 16499, Republic of Korea
| | - Jae Youn Cheong
- Department of Gastroenterology, Ajou University Hospital, Suwon 16499, Republic of Korea
| |
Collapse
|
2
|
Follow-up of the manganese-exposed workers healthy cohort (MEWHC) and biobank management from 2011 to 2017 in China. BMC Public Health 2018; 18:944. [PMID: 30068329 PMCID: PMC6090756 DOI: 10.1186/s12889-018-5880-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Accepted: 07/24/2018] [Indexed: 12/31/2022] Open
Abstract
Background Long-term excess exposure to environmental manganese (Mn) can lead to multi-system damage, especially in occupational populations. Therefore, we established a manganese-exposed workers healthy cohort (MEWHC), focusing on the systemic health effects related to Mn exposure. Here, we aimed to describe the follow-up activity for the MEWHC study and establish a standardized biological sample bank for the scientific management of high-quality biospecimens and the attached data from 2011 to 2017. Methods Baseline examinations for onsite workers were conducted, and the biobank for the MEWHC was first established in 2011; follow-up examinations occurred four times between July 2012 and November 2017. All questionnaires, clinical data and biological samples were routinely collected during each follow-up activity. Additional workers were recruited in 2016, which further enriched the resources of the biobank. Results A total of 2359 onsite workers and 612 retired workers at a ferromanganese refinery were enrolled in the prospective cohort, and their biological samples were obtained in the preliminary baseline survey and the follow-up investigation, including 2971 blood and urine samples from the cohort. In addition, 1524 hair samples, 1404 nail (toe and finger nails) and 1226 fecal samples were also collected. All specimens were preserved in the biobank, and the data were scientifically managed using a computer system. Conclusions The MEWHC study in China provides an effective way to obtain biological samples such as plasma, DNA, hair and urine for storage in a biobank for further study. The standardized management of various samples is crucial for accessing high-quality biospecimens. Electronic supplementary material The online version of this article (10.1186/s12889-018-5880-0) contains supplementary material, which is available to authorized users.
Collapse
|
3
|
Schmitt S, Kynast K, Schirmacher P, Herpel E. [Maintainance of a research tissue bank. (Infra)structural and quality aspects]. DER PATHOLOGE 2015; 36 Suppl 2:205-9. [PMID: 26391248 DOI: 10.1007/s00292-015-0083-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The availability of high quality human tissue samples and access to associated histopathological and clinical data are essential for biomedical research. Therefore, it is necessary to establish quality assured tissue biobanks that provide high quality tissue samples for research purposes. This entails quality concerns referring not only to the biomaterial specimen itself but encompassing all procedures related to biobanking, including the implementation of structural components, e.g. ethical and legal guidelines, quality management documentation as well as data and project management and information technology (IT) administration. Moreover, an integral aspect of tissue biobanks is the quality assured evaluation of every tissue specimen that is stored in a tissue biobank and used for projects to guarantee high quality assured biomaterial.
Collapse
Affiliation(s)
- S Schmitt
- NCT Tissue Bank, National Center for Tumor Diseases (NCT), Heidelberg, Deutschland
| | - K Kynast
- Institute of Pathology, Heidelberg University Hospital, Im Neuenheimer Feld 224, 69120, Heidelberg, Deutschland
| | - P Schirmacher
- Institute of Pathology, Heidelberg University Hospital, Im Neuenheimer Feld 224, 69120, Heidelberg, Deutschland
| | - E Herpel
- Institute of Pathology, Heidelberg University Hospital, Im Neuenheimer Feld 224, 69120, Heidelberg, Deutschland. .,NCT Tissue Bank, National Center for Tumor Diseases (NCT), Heidelberg, Deutschland.
| |
Collapse
|
4
|
Liu A, Pollard K. Biobanking for Personalized Medicine. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2015; 864:55-68. [PMID: 26420613 DOI: 10.1007/978-3-319-20579-3_5] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
A biobank is an entity that collects, processes, stores, and distributes biospecimens and relevant data for use in basic, translational, and clinical research. Biobanking of high-quality human biospecimens such as tissue, blood and other bodily fluids along with associated patient clinical information provides a fundamental scientific infrastructure for personalized medicine. Identification of biomarkers that are specifically associated with particular medical conditions such as cancer, cardiovascular disease and neurological disorders are useful for early detection, prevention, and treatment of the diseases. The ability to determine individual tumor biomarkers and to use those biomarkers for disease diagnosis, prognosis and prediction of response to therapy is having a very significant impact on personalized medicine and is rapidly changing the way clinical care is conducted. As a critical requirement for personalized medicine is the availability of a large collection of patient samples with well annotated patient clinical and pathological data, biobanks thus play an important role in personalized medicine advancement. The goal of this chapter is to explore the role of biobanks in personalized medicine and discuss specific needs regarding biobank development for translational and clinical research, especially for personalized medicine advancement.
Collapse
Affiliation(s)
- Angen Liu
- Biospecimen Repository, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 417 North Carolina Street, Room 302, Baltimore, MD, 21287, USA.
| | - Kai Pollard
- Biospecimen Repository, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 417 North Carolina Street, Room 302, Baltimore, MD, 21287, USA.
| |
Collapse
|
5
|
Minssen T, Schovsbo J. Legal aspects of biobanking as key issues for personalized medicine and translational exploitation. Per Med 2014; 11:497-508. [DOI: 10.2217/pme.14.29] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
This perspective article provides an overview on selected legal aspects of biobanking. It discusses these issues with a focus on public biobanks in a university setting and the specific challenges posed by personalized medicine. We conclude that any decisions as to the design of the regulatory environment should follow a process that takes account of the values, hopes and concerns of all stakeholders involved. In particular, we stress the importance of a careful planning of consent obligations combining traditional legal methods with an adequate institutional setup. In order to enhance the translational exploitation of biobanks, we further emphasize the pressing need to carefully consider a great variety of strategies and policy choices relating to intellectual property rights.
Collapse
Affiliation(s)
- Timo Minssen
- Centre for Information & Innovation Law (CIIR), University of Copenhagen, Faculty of Law, Studiegården, Studiestræde 6, 1455 Copenhagen, Denmark
| | - Jens Schovsbo
- Centre for Information & Innovation Law (CIIR), University of Copenhagen, Faculty of Law, Studiegården, Studiestræde 6, 1455 Copenhagen, Denmark
| |
Collapse
|
6
|
Braun L, Lesperance M, Mes-Massons AM, Tsao MS, Watson PH. Individual investigator profiles of biospecimen use in cancer research. Biopreserv Biobank 2014; 12:192-8. [PMID: 24918606 DOI: 10.1089/bio.2013.0092] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND Establishing targets for case accrual is an important component of a strategic plan for a biobank. We have previously assessed overall patterns of biospecimen use in cancer research publications in selected journals. Here we extend this analysis to consider patterns of biospecimen use in relation to cancer research programs developed by individual investigators. METHODS We selected three individual cancer research investigators whose independent research programs began circa 1986, have been characterized by extensive use of human tumor biospecimens, and have primarily involved translational research in the areas of breast, lung, and ovarian cancer. We analyzed biospecimen and data usage in their career publications categorized by numbers, type, and format, and accompanying annotating data in terms of conformance with BRISQ reporting and ethics related criteria. RESULTS Biospecimens were used in 313/474 (66%) of publications analyzed. The average number of biospecimens used by these research programs increased six-fold from less than 1000 in 2001-2003 to greater than 6000 in 2010-2012, and the average cohort sizes per article also increased from approximately 50 to 200 cases per study over the same period in most biospecimen categories (p<0.05). The relative proportions of different formats of biospecimens used has varied significantly and continues to change with the emergence of digital biospecimen derived data. In these three translational research programs, BRISQ elements relating to 'Biobank' categories were significantly less well reported for biospecimens used in publications than data corresponding to 'Clinical chart' categories (p<0001). CONCLUSIONS This study shows that overall use of biospecimens in cancer research has increased significantly and that dynamic variation in the relative use of different biospecimen formats has also occurred. This study also confirms our previous findings on patterns of biospecimen use and also those concerning incomplete reporting of relevant data elements that has not improved in the past decade.
Collapse
Affiliation(s)
- Lauren Braun
- 1 Tumour Tissue Repository, Trev and Joyce Deeley Research Centre, BC Cancer Agency , Victoria, British Columbia, Canada
| | | | | | | | | |
Collapse
|
7
|
Meir K, Gaffney EF, Simeon-Dubach D, Ravid R, Watson PH, Schacter B, Morente And The Marble Arch International Working Group On Biobanking MM. The human face of biobank networks for translational research. Biopreserv Biobank 2014; 9:279-85. [PMID: 24850340 DOI: 10.1089/bio.2011.0018] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The biobanking literature frequently addresses donor and societal issues surrounding biobanking, but the biobanker's perspective is rarely highlighted. While not comprehensive, this article offers an overview of the human aspects of biobanking from the viewpoint of biobank personnel-from biobank formation, through the process, and in addressing post-biobanking issues. As every biobank and biobank network may differ, such factors may vary. Before biobanking can commence, the purpose of the biobank network must be defined, and buy-in achieved from many stakeholders. An attitude of trust and sharing is essential, as is good communication. Developing a biobank is time consuming and laborious. Forming a network requires significantly more time due to the need for cross-institutional harmonization of policies, procedures, information technology considerations, and ethics. Circumstances may dictate whether development occurs top-down and/or bottom-up, as well as whether network management may be independent or by personnel from participating biobanks. Funding tends to be a prominent issue for biobanks and networks alike. In particular, networks function optimally with some level of government support, particularly for personnel. Quality biospecimen collection involves meticulously documented coordination with a network of medical and nursing staff. Examining and sampling operative specimens requires timely collaboration between the surgical and pathology teams. "Catch rates" for samples may be difficult to predict and may occur at a frequency less than anticipated due to factors related to the institution, staff, or specimen. These factors may affect specimen quality, and have a downstream effect on competition for specimens for research. Thus, release of samples requires a fair, carefully constructed sample access policy, usually incorporating an incentive for researchers, and an encouragement to form collaborations. Finally, the public and patient groups should aim to understand the benefits of a biobank network, so that patient care is improved through coordinated biobanking activity.
Collapse
Affiliation(s)
- Karen Meir
- 1 Department of Pathology, Hadassah-Hebrew University Medical Center , Jerusalem, Israel
| | | | | | | | | | | | | |
Collapse
|
8
|
Suh KS, Sarojini S, Youssif M, Nalley K, Milinovikj N, Elloumi F, Russell S, Pecora A, Schecter E, Goy A. Tissue banking, bioinformatics, and electronic medical records: the front-end requirements for personalized medicine. JOURNAL OF ONCOLOGY 2013; 2013:368751. [PMID: 23818899 PMCID: PMC3683471 DOI: 10.1155/2013/368751] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/07/2013] [Revised: 05/03/2013] [Accepted: 05/07/2013] [Indexed: 11/26/2022]
Abstract
Personalized medicine promises patient-tailored treatments that enhance patient care and decrease overall treatment costs by focusing on genetics and "-omics" data obtained from patient biospecimens and records to guide therapy choices that generate good clinical outcomes. The approach relies on diagnostic and prognostic use of novel biomarkers discovered through combinations of tissue banking, bioinformatics, and electronic medical records (EMRs). The analytical power of bioinformatic platforms combined with patient clinical data from EMRs can reveal potential biomarkers and clinical phenotypes that allow researchers to develop experimental strategies using selected patient biospecimens stored in tissue banks. For cancer, high-quality biospecimens collected at diagnosis, first relapse, and various treatment stages provide crucial resources for study designs. To enlarge biospecimen collections, patient education regarding the value of specimen donation is vital. One approach for increasing consent is to offer publically available illustrations and game-like engagements demonstrating how wider sample availability facilitates development of novel therapies. The critical value of tissue bank samples, bioinformatics, and EMR in the early stages of the biomarker discovery process for personalized medicine is often overlooked. The data obtained also require cross-disciplinary collaborations to translate experimental results into clinical practice and diagnostic and prognostic use in personalized medicine.
Collapse
Affiliation(s)
- K. Stephen Suh
- The Genomics and Biomarkers Program, The John Theurer Cancer Center at Hackensack, University Medical Center, D. Jurist Research Building, 40 Prospect Avenue, Hackensack, NJ 07601, USA
| | - Sreeja Sarojini
- The Genomics and Biomarkers Program, The John Theurer Cancer Center at Hackensack, University Medical Center, D. Jurist Research Building, 40 Prospect Avenue, Hackensack, NJ 07601, USA
| | - Maher Youssif
- The Genomics and Biomarkers Program, The John Theurer Cancer Center at Hackensack, University Medical Center, D. Jurist Research Building, 40 Prospect Avenue, Hackensack, NJ 07601, USA
| | - Kip Nalley
- Sophic Systems Alliance Inc., 20271 Goldenrod Lane, Germantown, MD 20876, USA
| | - Natasha Milinovikj
- The Genomics and Biomarkers Program, The John Theurer Cancer Center at Hackensack, University Medical Center, D. Jurist Research Building, 40 Prospect Avenue, Hackensack, NJ 07601, USA
| | - Fathi Elloumi
- Sophic Systems Alliance Inc., 20271 Goldenrod Lane, Germantown, MD 20876, USA
| | - Steven Russell
- Siemens Corporate Research, IT Platforms, Princeton, NJ 08540, USA
| | - Andrew Pecora
- The Genomics and Biomarkers Program, The John Theurer Cancer Center at Hackensack, University Medical Center, D. Jurist Research Building, 40 Prospect Avenue, Hackensack, NJ 07601, USA
| | | | - Andre Goy
- The Genomics and Biomarkers Program, The John Theurer Cancer Center at Hackensack, University Medical Center, D. Jurist Research Building, 40 Prospect Avenue, Hackensack, NJ 07601, USA
| |
Collapse
|
9
|
Mee BC, Carroll P, Donatello S, Connolly E, Griffin M, Dunne B, Burke L, Flavin R, Rizkalla H, Ryan C, Hayes B, D'Adhemar C, Banville N, Faheem N, Muldoon C, Gaffney EF. Maintaining Breast Cancer Specimen Integrity and Individual or Simultaneous Extraction of Quality DNA, RNA, and Proteins from Allprotect-Stabilized and Nonstabilized Tissue Samples. Biopreserv Biobank 2011; 9:389-398. [PMID: 23386926 PMCID: PMC3558729 DOI: 10.1089/bio.2011.0034] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2011] [Accepted: 08/25/2011] [Indexed: 12/13/2022] Open
Abstract
The Saint James's Hospital Biobank was established in 2008, to develop a high-quality breast tissue BioResource, as a part of the breast cancer clinical care pathway. The aims of this work were: (1) to ascertain the quality of RNA, DNA, and protein in biobanked carcinomas and normal breast tissues, (2) to assess the efficacy of AllPrep(®) (Qiagen) in isolating RNA, DNA, and protein simultaneously, (3) to compare AllPrep with RNEasy(®) and QIAamp(®) (both Qiagen), and (4) to examine the effectiveness of Allprotect(®) (Qiagen), a new tissue stabilization medium in preserving DNA, RNA, and proteins. One hundred eleven frozen samples of carcinoma and normal breast tissue were analyzed. Tumor and normal tissue morphology were confirmed by frozen sections. Tissue type, tissue treatment (Allprotect vs. no Allprotect), extraction kit, and nucleic acid quantification were analyzed by utilizing a 4 factorial design (SPSS PASW 18 Statistics Software(®)). QIAamp (DNA isolation), AllPrep (DNA, RNA, and Protein isolation), and RNeasy (RNA isolation) kits were assessed and compared. Mean DNA yield and A(260/280) values using QIAamp were 33.2 ng/μL and 1.86, respectively, and using AllPrep were 23.2 ng/μL and 1.94. Mean RNA yield and RNA Integrity Number (RIN) values with RNeasy were 73.4 ng/μL and 8.16, respectively, and with AllPrep were 74.8 ng/μL and 7.92. Allprotect-treated tissues produced higher RIN values of borderline significance (P=0.055). No discernible loss of RNA stability was detected after 6 h incubation of stabilized or nonstabilized tissues at room temperature or 4°C or in 9 freeze-thaw cycles. Allprotect requires further detailed evaluation, but we consider AllPrep to be an excellent option for the simultaneous extraction of RNA, DNA, and protein from tumor and normal breast tissues. The essential presampling procedures that maintain the diagnostic integrity of pathology specimens do not appear to compromise the quality of molecular isolates.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Ciara Ryan
- St. James's Hospital Biobank, Dublin, Ireland
| | - Brian Hayes
- St. James's Hospital Biobank, Dublin, Ireland
| | | | | | | | | | | |
Collapse
|
10
|
Abstract
PURPOSE OF REVIEW Biobanking has been identified as a key area for development in order to accelerate the discovery and development of new drugs. This review describes the recent advances in the field of biobanking and biospecimen research, with special reference to tumour banks which are the biobanks of primary interest in oncology. RECENT FINDINGS There is a dramatic deficiency of high-quality, well annotated cancer biospecimens. Biospecimen research is a fast developing field that will improve biobanking methodology and biobanking is becoming more professionally organized with increased attention to quality management. Biobank networks are developing rapidly in order to combine and share resources. SUMMARY Biobanking services must improve rapidly to serve the needs of personalized medicine and biospecimen research should be encouraged and supported at all levels from project funding to publication of results. Biobanks need to be run to high professional standards and the importance of adequate funding, training and certification must be emphasized. The growing presence of national and international biobank networks will allow biobanks to synergize. The development of a biobanking community will facilitate teamwork to overcome common challenges and enhance communication with multiple stakeholder groups.
Collapse
|